Form 4: iRhythm Executive Sells Shares Under 10b5-1 Plan

iRhythm Holdings EVP Mervin Smith sold 2,585 shares of common stock for $114.3 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Mervin Smith, Executive Vice President of Strategic Business Operations at iRhythm Holdings, Inc. (IRTC), reported a sale of common stock.
• The transaction involved the disposition of 2,585 shares of iRhythm Holdings common stock.
• The shares were sold at a price of $114.3 per share.
• The sale occurred on March 16, 2026, with a deemed execution date also on March 16, 2026.
• Following this transaction, Mervin Smith beneficially owns 23,027 shares of common stock directly.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was established by the reporting person on November 19, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine insider transaction executed under a pre-established 10b5-1 plan, which typically does not carry significant positive or negative implications for the company's operational or financial performance.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 plan are common practice among executives in the medical device and healthcare technology sectors. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, helping them avoid accusations of trading on material non-public information. Such routine sales are generally not indicative of management's view on the company's future prospects.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan by iRhythm Holdings' EVP Mervin Smith aligns with standard corporate governance practices for managing insider stock transactions, similar to executives at companies like Dexcom (DXCM) or Insulet (PODD) who frequently utilize such plans for liquidity and diversification.
• The reported sale volume of 2,585 shares represents a relatively small portion of the executive's total holdings (23,027 shares remaining), which is typical for routine diversification or liquidity events rather than a significant divestment, comparable to similar-sized transactions seen at peer companies in the health tech space.

Stakeholder Impact

• Shareholders: A routine insider sale under a 10b5-1 plan is generally not expected to have a material impact on shareholder sentiment or the company's valuation, as it is a pre-scheduled event for personal financial planning.

Key Dates

Keywords

iRhythm Holdings, IRTC, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, Mervin Smith